Tag: 200-300

On September 7, 2021, Cho, Won Je published a patent.Name: 3-(Naphthalen-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde The title of the patent was Preparation of pyrazolecarboxamide for preventing or treating metabolic disease. And the patent contained the following:

The present invention relates to a novel pyrazolecarboxamide carboxamide compound I [R1 = H, 3-OMe, 3,4-(OMe)2, 4-Me; R2 = H, CF3, NH2; OR3 = meta-(3-pyridinyloxy), para-(4-isopropylphenyl), para-(2-methoxy-4-methylphenyl), etc.] and a composition for preventing or treating metabolic diseases, wherein the composition is a potent and selective estrogen-related receptor (ERR) γ inverse agonist with excellent selectivity and since it shows affinity, it can be effectively used for treatment of metabolic diseases. For example, II was prepared and exhibited IC50 of 1.33μM against estrogen-related receptor (ERR) γ. The experimental process involved the reaction of 3-(Naphthalen-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde(cas: 36640-53-6).Name: 3-(Naphthalen-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde

The Article related to preparation pyrazolecarboxamide treatment metabolic disease, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Name: 3-(Naphthalen-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On March 5, 2020, Hinklin, Ronald Jay; Allen, Shelley; Barbour, Patrick; Cook, Adam; Dahlke, Joshua; Gaudino, John; Laird, Ellen; Mcnulty, Oren T.; Zhao, Qian published a patent.Quality Control of 1-(4-Methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-4-ol The title of the patent was Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases and their preparation. And the patent contained the following:

Provided herein are compounds of the formula I and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, which are inhibitors of one or more TAM kinases and/or c-Met kinase, and are useful in the treatment and prevention of diseases which can be treated with a TAM kinase inhibitor and/or a c-Met kinase inhibitor. Compounds of formula I wherein X1 is CH2 and N; R1 is H and C1-6 alkyl; R2 is H, C1-6 alkyl, C1-6 hydroxyalkyl, (un)substituted 3- to 4-membered cycloalkyl, etc.; R9 is H and halo; G is (un)substituted 5- to 6-membered oxoheterocyclyl and (un)substituted oxoquinolinyl; and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by N-(3-fluoro-4-((3-iodo-1-(4-methoxybenzyl)-lH-pyrazolo[3,4-b]pyridin-4-yl)oxy)phenyl)-2-(4-fluorophenyl)-3-oxo-2,3-dihydropyridazine-4-carboxamide with ethanolamine; the resulting N-(3-fluoro-4-((3-((2-hydroxyethyl)amino)-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-4-yl)oxy)phenyl)-2-(4-fluorophenyl)-3-oxo-2,3-dihydropyridazine-4-carboxamide underwent hydrolysis to give compound II. The invention compounds were evaluated for their TAM and MET kinase inhibitory activity (data given). The experimental process involved the reaction of 1-(4-Methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-4-ol(cas: 924909-16-0).Quality Control of 1-(4-Methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-4-ol

The Article related to pyrazolopyridine preparation tam met kinase inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Quality Control of 1-(4-Methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-4-ol

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On May 24, 2018, Gavrilov, Aleksey Sergeevich; Aleshunin, Pavel Aleksandrovich; Gorbunova, Svetlana Leonidovna; Rekharsky, Mikhail Vladimirovich; Kozhemyakina, Natalia Vladimirovna; Kukushkina, Anna Aleksandrovna; Kushakova, Anna Sergeevna; Mikhaylov, Leonid Evgen’evich; Moldavsky, Alexander; Popkova, Aleksandra Vladimirovna; Silonov, Sergey Aleksandrovich; Smirnova, Svetlana Sergeevna; Iakovlev, Pavel Andreevich published a patent.Synthetic Route of 924909-16-0 The title of the patent was Pyrazolopyridine and indazole derivatives as inhibitors of Bruton’s tyrosine kinase and their preparation. And the patent contained the following:

The invention relates to a compound of formula I or pharmaceutically acceptable salt, solvate or stereoisomer thereof, which have properties of inhibitor of Bruton’s tyrosine kinase (Btk), to pharmaceutical compositions containing such compounds, and their use as pharmaceuticals for treatment of diseases and disorder. Compounds of formula I wherein V1 is C and N; V2 is CR2 and N; M is absent and CH2; K is absent and LR3; L is CH2, NH, O and a bond; R1 is (un)substituted 4-(4-oxo-4H-pyridin-1-yl)aryl, (un)substituted 4-(aryloxy)aryl, (un)substituted 4-(arylaminocarbonyl)aryl, etc.; R2 and R11 are independently H, D,halo, CN, C1-6 alkoxy, etc.; R3 is H, halo, CN, OH, C1-6 alkyl, etc.; R6 is N-substituted azetidin-3-yl, N-substituted pyrrolidinyl, and N-substituted piperidin-3-yl; and pharmaceutically acceptable salts, solvates, and stereoisomers thereof, are claimed. Example compound II was prepared by a general procedure (procedure given). The invention compounds were evaluated for their BTK inhibitory activity (data given). The experimental process involved the reaction of 1-(4-Methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-4-ol(cas: 924909-16-0).Synthetic Route of 924909-16-0

The Article related to pyrazolopyridine indazole preparation bth inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Synthetic Route of 924909-16-0

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On June 24, 2021, Cotesta, Simona; Gerspacher, Marc; Leblanc, Catherine; Liu, Bo; Lorthiois, Edwige Liliane Jeanne; Machauer, Rainier; Mah, Robert; Mura, Christophe; Rigollier, Pascal; Schneider, Nadine; Stutz, Stefan; Vaupel, Andrea; Warin, Nicolas; Wilcken, Rainer published a patent.Formula: C7H6BrN3 The title of the patent was Pyrazolyl derivatives useful as anti-cancer agents. And the patent contained the following:

Pyrazolyl derivatives of formula I [A = cycloalkyl, heterocyclyl, aryl, heteroaryl, etc.; B = aryl, heteroaryl, etc.; C = H, alkyl, cycloalkyl, fluoroalkyl, CN, CH2OH, etc.; L = spirocycloalkyl, etc.; G = COCH=CH2, COCCH, SO2-alkylene, etc.] or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, are prepared as anticancer agents. Thus, (R)-II was prepared, and had IC50 value of 0.017μM in KRASG12C covalent competition assay. The experimental process involved the reaction of 5-Bromo-2-methyl-2H-pyrazolo[3,4-c]pyridine(cas: 2089292-88-4).Formula: C7H6BrN3

The Article related to pyrazolyl derivative preparation anticancer, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Formula: C7H6BrN3

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On June 24, 2021, Liu, Bo; Cotesta, Simona; Gerspacher, Marc; Leblanc, Catherine; Lorthiois, Edwige Liliane Jeanne; Machauer, Rainer; Mah, Robert; Mura, Christophe; Rigollier, Pascal; Schneider, Nadine; Stutz, Stefan; Vaupel, Andrea; Warin, Nicolas; Wilcken, Rainer published a patent.Product Details of 2089292-88-4 The title of the patent was Pyrazole derivatives as anti-cancer agents and preparation. And the patent contained the following:

The invention relates compounds of formula I, us as anti-cancer agents in the ability to inhibit KRASG12C and their preparation Compound I, wherein A is (un)substituted C5-7, (un)substituted C5-10, (un)substituted 5- to 7-membered unsaturated heterocyclyl containing one carbon-carbon double bond and one oxygen, etc.; B selected from the group of B1 and B2; B1 is (un)substituted C6-10 with 1, 2, 3 and 4 RBa; B2 is 6- to 13-membered heteroaryl containing 1, 2 and 3 nitrogen atoms and is (un)substituted 1, 2, 3 and 4 RBb; each RBa is independently hydroxy, C1-4 alkyl, halo, etc.; each RBb is independently C1-4 alkyl; cyclopropyl, halo, etc.; C is hydrogen, C1-3 alkyl, C3-5 cycloalkyl, etc.; L is (un)substituted 2-azaspiro[3.3]heptanyl, (un)substituted 2-azaspiro[3.4]heptanyl, pyrrolidine, etc.; D is (un)substituted prop-2-en-1-one, (un)substituted prop-2-yn-1-one, etc.; and stereoisomers, atropisomers, pharmaceutically acceptable salts, thereof, are claimed. Conmpound II was prepared using a multistep procedure (procedure given). Compound II was evaluated for KRAS G12C inhibitory activity yielding an IC50 of 0.017μM. Compounds of the invention were evaluated for KRAS G12C inhibitory activity (data given). The experimental process involved the reaction of 5-Bromo-2-methyl-2H-pyrazolo[3,4-c]pyridine(cas: 2089292-88-4).Product Details of 2089292-88-4

The Article related to pyrazole preparation cancer kras inhibition, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Product Details of 2089292-88-4

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

Arbaciauskiene, Egle; Martynaitis, Vytas; Krikstolaityte, Sonata; Holzer, Wolfgang; Sackusa, Algirdas published an article in 2011, the title of the article was Synthesis of 3-substituted 1-phenyl-1H-pyrazole-4-carbaldehydes and the corresponding ethanones by Pd-catalyzed cross-coupling reactions.Reference of 3-(Naphthalen-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde And the article contains the following content:

An efficient synthetic route to construct substituted 1-phenyl-1H-pyrazole-4-carboxaldehydes and the corresponding ethanones was described and the synthesis of the target compounds was achieved using 1-phenyl-1H-pyrazol-3-ol as a starting material. Carbon-carbon bond-forming palladium-catalyzed cross-coupling reactions were applied for the functionalization of the intermediate pyrazole triflates [i.e., trifluoromethanesulfonic acid 1-phenyl-1H-pyrazol-3-yl ester derivatives]. The target compounds thus formed included imidazo[4,3-c]pyridine derivatives, 1,3-diphenyl-1H-pyrazole-4-carboxaldehyde, 1-phenyl-3-(3-thienyl)-1H-pyrazole-4-carboxaldehyde, 1-(1,3-diphenyl-1H-pyrazol-4-yl)ethanone, etc. The experimental process involved the reaction of 3-(Naphthalen-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde(cas: 36640-53-6).Reference of 3-(Naphthalen-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde

The Article related to pyrazolol triflate preparation palladium catalyzed cross coupling, pyrazolecarboxaldehyde preparation, ethanone pyrazolyl preparation, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Reference of 3-(Naphthalen-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On September 30, 2014, Ashok, D.; Ganesh, Arram; Ravi, S.; Lakshmi, B. Vijaya published an article.Reference of 3-(Naphthalen-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde The title of the article was Solvent-free microwave assisted synthesis and antimicrobial activity of new 2-{4-[3-(1-phenyl-3-aryl-1H-pyrazol-4-yl)-acryloyl]-phenyl}-isoindole-1,3-diones. And the article contained the following:

A series of new 2-(4-(3-(1-phenyl-3-aryl-1H-pyrazol-4-yl)-acryloyl)-phenyl)-isoindole-1,3-diones I (Ar = C6H5, 4-MeC6H4, 4-MeOC6H4, 4-BrC6H4, 2-naphthyl, etc.) have been synthesized by Claisen-Schmidt condensation of 2-(4-acetylphenyl)-isoindole-1,3-dione with 1-phenyl-3-aryl-1H-pyrazole-4-carbaldehydes in the presence of basic alumina under solvent-free microwave irradiation and conventional heating methods. All the synthesized compounds were screened for their antimicrobial activity. The activity was determined using cup plate agar diffusion method by measuring the zone of inhibition in mm. From the screening studies it is evident that the synthesized compounds I (Ar = Ph, 4-MeC6H4, 2-naphthyl) showed good antibacterial activity and compounds I (Ar = 4-MeOC6H4, 2-naphthyl) showed good antifungal activity against all the tested organisms. The experimental process involved the reaction of 3-(Naphthalen-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde(cas: 36640-53-6).Reference of 3-(Naphthalen-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde

The Article related to pyrazolyl acryloyl phenylisoindoledione preparation green chem microwave irradiation, solvent free antibacterial antifungal, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Reference of 3-(Naphthalen-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On September 30, 2002, Vovk, M. V.; Mel’nichenko, N. V.; Chornous, V. A.; Bratenko, M. K. published an article.Formula: C20H14N2O The title of the article was Intramolecular cyclization of 4-isocyanato-3-(2-naphthyl)-1-phenylpyrazole under friedel-crafts reaction conditions. And the article contained the following:

4-Isocyanato-3-(2-naphthyl)-1-phenylpyrazole cyclized under the influence of AlCl3 to give 2H-benzo-[h]pyrazolo[4,3-c]isoquinoline. The experimental process involved the reaction of 3-(Naphthalen-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde(cas: 36640-53-6).Formula: C20H14N2O

The Article related to isocyanatonaphthylphenylpyrazole intramol cyclization friedel crafts condition, benzopyrazoloisoquinoline preparation, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Formula: C20H14N2O

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On December 20, 2019, Xu, Zichen; Wei, Wanguo; Fang, Xianjie; Liu, Rufeng; Yi, Mingyue; Zhou, Chenglong; Liu, Jie published a patent.Computed Properties of 1187582-58-6 The title of the patent was Preparation method of N-[(1S)-2-[3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl]-1-methylethyl]-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide as androgen receptor antagonist. And the patent contained the following:

The invention relates to a process for the preparation of N-[(1S)-2-[3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl]-1-methylethyl]-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide as androgen receptor antagonist. For instance, Suzuki reaction of 2-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-benzonitrile with 5-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole followed by deprotection, N-alkylation with N-Boc-L-alaninol, amidation with 5-acetyl-1H-pyrazole-3-carboxylic acid Et ester, and reduction to give N-[(1S)-2-[3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl]-1-methylethyl]-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide. The experimental process involved the reaction of 5-Bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole(cas: 1187582-58-6).Computed Properties of 1187582-58-6

The Article related to chlorocyanophenyl pyrazolylmethylethylhydroxyethyl pyrazolecarboxamide preparation suzuki alkylation amidation, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Computed Properties of 1187582-58-6

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On August 12, 1975, Wikel, James H. published a patent.COA of Formula: C11H9N3O4 The title of the patent was 5-(2-Aminophenyl)pyrazole-3-carboxylic acids and esters. And the patent contained the following:

MeO2CCO2Me was treated with MeCOC6H4NO2-2 and the o-O2NC6H4COCH2COCO2Et cyclized with H2NNH2 to give I (R = NO2), which was reduced to I (R = NH2). At 1-200 mg/kg I (R = NH2) was a complement inhibitor. The experimental process involved the reaction of Methyl 3-(2-nitrophenyl)-1H-pyrazole-5-carboxylate(cas: 57446-04-5).COA of Formula: C11H9N3O4

The Article related to complement inhibitor aminophenylpyrazolecarboxylate, pyrazolecarboxylate aminophenyl complement inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.COA of Formula: C11H9N3O4

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics